» Articles » PMID: 16773710

Estrogens and the Pathophysiology of the Biliary Tree

Overview
Specialty Gastroenterology
Date 2006 Jun 15
PMID 16773710
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The scientific framework concerning estrogen effects on different tissues has expanded enormously during the last decades, when estrogen receptor (ER) subtypes were identified. Estrogens are not only essential for the female reproductive system, but they also control fundamental functions in other tissues including the cardiovascular system, bone, brain and liver. Recently, estrogens have been shown to target the biliary tree, where they modulate the proliferative and secretory activities of cholangiocytes, the epithelial cells lining bile ducts. By acting on both estrogen receptors (ER-alpha) and (ER-beta) subtypes, and by activating either genomic or non-genomic pathways, estrogens play a key role in the complex loop of growth factors and cytokines, which modulates the proliferative response of cholangiocytes to damage. Specifically, estrogens activate intracellular signalling cascades [ERK(1/2) (extracellular regulated kinases (1/2), PI3- kinase/AKT (phosphatidylinositol-3' kinase/AKT)] typical of growth factors such as insulin like growth factor (IGF1), nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), thus potentiating their action. In addition, estrogens stimulate the secretion of different growth factors in proliferating cholangiocytes. This review specifically deals with the recent advances related to the role and mechanisms by which estrogens modulate cholangiocyte functions in normal and pathological conditions.

Citing Articles

Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.

Di Stasi V, Contaldo A, Birtolo L, Shahini E Cancers (Basel). 2024; 16(19).

PMID: 39410050 PMC: 11476000. DOI: 10.3390/cancers16193432.


Are Gender Differences Important for Autoimmune Liver Diseases?.

Floreani A, Gabbia D, De Martin S Life (Basel). 2024; 14(4).

PMID: 38672770 PMC: 11050899. DOI: 10.3390/life14040500.


Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease.

Kim Y, Park H, Ryu H, Kim Y, Ahn C, Lee K J Korean Med Sci. 2023; 38(38):e296.

PMID: 37750370 PMC: 10519778. DOI: 10.3346/jkms.2023.38.e296.


DHEA and Its Metabolites Reduce the Cytokines Involved in the Inflammatory Response and Fibrosis in Primary Biliary Cholangitis.

Blatkiewicz M, Sielatycka K, Piotrowska K, Kilanczyk E Int J Mol Sci. 2023; 24(6).

PMID: 36982376 PMC: 10049419. DOI: 10.3390/ijms24065301.


Urinary Metabolic Profiling of Liver Fluke-Induced Cholangiocarcinoma-A Follow-Up Study.

Alsaleh M, Sithithaworn P, Khuntikeo N, Loilome W, Yongvanit P, Hughes T J Clin Exp Hepatol. 2023; 13(2):203-217.

PMID: 36950498 PMC: 10025591. DOI: 10.1016/j.jceh.2022.11.012.


References
1.
Everson G . Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin Proc. 1990; 65(7):1020-5. DOI: 10.1016/s0025-6196(12)65165-9. View

2.
Lakoski S, Herrington D . Effects of oestrogen receptor-active compounds on lipid metabolism. Diabetes Obes Metab. 2005; 7(5):471-7. DOI: 10.1111/j.1463-1326.2004.00412.x. View

3.
Wiesner R, Batts K, Krom R . Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Liver Transpl Surg. 1999; 5(5):388-400. DOI: 10.1002/lt.500050519. View

4.
Desmet , van Eyken P , Roskams . Histopathology of vanishing bile duct diseases. Adv Clin Path. 1999; 2(2):87-99. View

5.
Desai P, Nallani S, Sane R, Moore L, Goodwin B, Buckley D . Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002; 30(5):608-12. DOI: 10.1124/dmd.30.5.608. View